http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 20 Jul 2026 07:13:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Armata+Pharmaceuticals%2C+++For%3A+Jul+17/26786942.html si-local-file:///var/storage/secattach/20260720/26786942.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Armata+Pharmaceuticals%2C+++For%3A+Jul+17/26786942.html Mon, 20 Jul 2026 07:13:00 -0400 ARMP O.00168871 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Armata+Pharmaceuticals%2C+++For%3A+Jul+17/26786942.html si-local-file:///var/storage/secattach/20260720/26786942.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Armata+Pharmaceuticals%2C+++For%3A+Jul+17/26786942.html Mon, 20 Jul 2026 07:13:00 -0400 ARMP O.00168871 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Armata+Pharmaceuticals%2C+++For%3A+Jul+20/26786948.html si-local-file:///var/storage/secattach/20260720/26786948.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Armata+Pharmaceuticals%2C+++For%3A+Jul+20/26786948.html Mon, 20 Jul 2026 07:13:00 -0400 ARMP O.00168871 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Armata+Pharmaceuticals%2C+++For%3A+Jul+20/26786948.html si-local-file:///var/storage/secattach/20260720/26786948.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Armata+Pharmaceuticals%2C+++For%3A+Jul+20/26786948.html Mon, 20 Jul 2026 07:13:00 -0400 ARMP O.00168871 http://www.streetinsider.com/FDA/Armata+submits+Phase+3+protocol+to+FDA+for+bacteriophage+drug+AP-SA02/26786839.html <p>Armata Pharmaceuticals (NYSE American: ARMP) has submitted its complete Phase 3 superiority protocol to the U.S. Food and Drug Administration for AP-SA02, its bacteriophage product candidate targeting <i>Staphylococcus aureus</i> bacteremia, according to a press release dated July 20, 2026.</p> <p>The company also submitted responses to all FDA comments on clinical, chemistry, manufacturing, and controls topics raised during the End-of-Phase 2 meeting. Armata said it has completed four engineering runs of AP-SA02 at its manufacturing facility in Los Angeles, with production of clinical trial material identified as the next planned step.</p> <p>The company said its Phase 3 study remains on track to begin http://www.streetinsider.com/FDA/Armata+submits+Phase+3+protocol+to+FDA+for+bacteriophage+drug+AP-SA02/26786839.html Mon, 20 Jul 2026 07:00:32 -0400 A.06822034 A.38032151 A.40958841 ARMP O.00168871 O.00366519 O.20026344 O.36670513 http://www.streetinsider.com/FDA/Armata+submits+Phase+3+protocol+to+FDA+for+bacteriophage+drug+AP-SA02/26786839.html <p>Armata Pharmaceuticals (NYSE American: ARMP) has submitted its complete Phase 3 superiority protocol to the U.S. Food and Drug Administration for AP-SA02, its bacteriophage product candidate targeting <i>Staphylococcus aureus</i> bacteremia, according to a press release dated July 20, 2026.</p> <p>The company also submitted responses to all FDA comments on clinical, chemistry, manufacturing, and controls topics raised during the End-of-Phase 2 meeting. Armata said it has completed four engineering runs of AP-SA02 at its manufacturing facility in Los Angeles, with production of clinical trial material identified as the next planned step.</p> <p>The company said its Phase 3 study remains on track to begin http://www.streetinsider.com/FDA/Armata+submits+Phase+3+protocol+to+FDA+for+bacteriophage+drug+AP-SA02/26786839.html Mon, 20 Jul 2026 07:00:32 -0400 A.06822034 A.38032151 A.40958841 ARMP O.00168871 O.00366519 O.20026344 O.36670513 http://www.streetinsider.com/FDA/Armata+submits+Phase+3+protocol+to+FDA+for+bacteriophage+drug+AP-SA02/26786839.html <p>Armata Pharmaceuticals (NYSE American: ARMP) has submitted its complete Phase 3 superiority protocol to the U.S. Food and Drug Administration for AP-SA02, its bacteriophage product candidate targeting <i>Staphylococcus aureus</i> bacteremia, according to a press release dated July 20, 2026.</p> <p>The company also submitted responses to all FDA comments on clinical, chemistry, manufacturing, and controls topics raised during the End-of-Phase 2 meeting. Armata said it has completed four engineering runs of AP-SA02 at its manufacturing facility in Los Angeles, with production of clinical trial material identified as the next planned step.</p> <p>The company said its Phase 3 study remains on track to begin http://www.streetinsider.com/FDA/Armata+submits+Phase+3+protocol+to+FDA+for+bacteriophage+drug+AP-SA02/26786839.html Mon, 20 Jul 2026 07:00:32 -0400 A.06822034 A.38032151 A.40958841 ARMP O.00168871 O.00366519 O.20026344 O.36670513 http://www.streetinsider.com/FDA/Armata+submits+Phase+3+protocol+to+FDA+for+bacteriophage+drug+AP-SA02/26786839.html <p>Armata Pharmaceuticals (NYSE American: ARMP) has submitted its complete Phase 3 superiority protocol to the U.S. Food and Drug Administration for AP-SA02, its bacteriophage product candidate targeting <i>Staphylococcus aureus</i> bacteremia, according to a press release dated July 20, 2026.</p> <p>The company also submitted responses to all FDA comments on clinical, chemistry, manufacturing, and controls topics raised during the End-of-Phase 2 meeting. Armata said it has completed four engineering runs of AP-SA02 at its manufacturing facility in Los Angeles, with production of clinical trial material identified as the next planned step.</p> <p>The company said its Phase 3 study remains on track to begin http://www.streetinsider.com/FDA/Armata+submits+Phase+3+protocol+to+FDA+for+bacteriophage+drug+AP-SA02/26786839.html Mon, 20 Jul 2026 07:00:32 -0400 A.06822034 A.38032151 A.40958841 ARMP O.00168871 O.00366519 O.20026344 O.36670513 http://www.streetinsider.com/FDA/Armata+submits+Phase+3+protocol+to+FDA+for+bacteriophage+drug+AP-SA02/26786839.html <p>Armata Pharmaceuticals (NYSE American: ARMP) has submitted its complete Phase 3 superiority protocol to the U.S. Food and Drug Administration for AP-SA02, its bacteriophage product candidate targeting <i>Staphylococcus aureus</i> bacteremia, according to a press release dated July 20, 2026.</p> <p>The company also submitted responses to all FDA comments on clinical, chemistry, manufacturing, and controls topics raised during the End-of-Phase 2 meeting. Armata said it has completed four engineering runs of AP-SA02 at its manufacturing facility in Los Angeles, with production of clinical trial material identified as the next planned step.</p> <p>The company said its Phase 3 study remains on track to begin http://www.streetinsider.com/FDA/Armata+submits+Phase+3+protocol+to+FDA+for+bacteriophage+drug+AP-SA02/26786839.html Mon, 20 Jul 2026 07:00:32 -0400 A.06822034 A.38032151 A.40958841 ARMP O.00168871 O.00366519 O.20026344 O.36670513 http://www.streetinsider.com/FDA/Armata+submits+Phase+3+protocol+to+FDA+for+bacteriophage+drug+AP-SA02/26786839.html <p>Armata Pharmaceuticals (NYSE American: ARMP) has submitted its complete Phase 3 superiority protocol to the U.S. Food and Drug Administration for AP-SA02, its bacteriophage product candidate targeting <i>Staphylococcus aureus</i> bacteremia, according to a press release dated July 20, 2026.</p> <p>The company also submitted responses to all FDA comments on clinical, chemistry, manufacturing, and controls topics raised during the End-of-Phase 2 meeting. Armata said it has completed four engineering runs of AP-SA02 at its manufacturing facility in Los Angeles, with production of clinical trial material identified as the next planned step.</p> <p>The company said its Phase 3 study remains on track to begin http://www.streetinsider.com/FDA/Armata+submits+Phase+3+protocol+to+FDA+for+bacteriophage+drug+AP-SA02/26786839.html Mon, 20 Jul 2026 07:00:32 -0400 A.06822034 A.38032151 A.40958841 ARMP O.00168871 O.00366519 O.20026344 O.36670513 http://www.streetinsider.com/FDA/Armata+submits+Phase+3+protocol+to+FDA+for+bacteriophage+drug+AP-SA02/26786839.html <p>Armata Pharmaceuticals (NYSE American: ARMP) has submitted its complete Phase 3 superiority protocol to the U.S. Food and Drug Administration for AP-SA02, its bacteriophage product candidate targeting <i>Staphylococcus aureus</i> bacteremia, according to a press release dated July 20, 2026.</p> <p>The company also submitted responses to all FDA comments on clinical, chemistry, manufacturing, and controls topics raised during the End-of-Phase 2 meeting. Armata said it has completed four engineering runs of AP-SA02 at its manufacturing facility in Los Angeles, with production of clinical trial material identified as the next planned step.</p> <p>The company said its Phase 3 study remains on track to begin http://www.streetinsider.com/FDA/Armata+submits+Phase+3+protocol+to+FDA+for+bacteriophage+drug+AP-SA02/26786839.html Mon, 20 Jul 2026 07:00:32 -0400 A.06822034 A.38032151 A.40958841 ARMP O.00168871 O.00366519 O.20026344 O.36670513 http://www.streetinsider.com/FDA/Armata+submits+Phase+3+protocol+to+FDA+for+bacteriophage+drug+AP-SA02/26786839.html <p>Armata Pharmaceuticals (NYSE American: ARMP) has submitted its complete Phase 3 superiority protocol to the U.S. Food and Drug Administration for AP-SA02, its bacteriophage product candidate targeting <i>Staphylococcus aureus</i> bacteremia, according to a press release dated July 20, 2026.</p> <p>The company also submitted responses to all FDA comments on clinical, chemistry, manufacturing, and controls topics raised during the End-of-Phase 2 meeting. Armata said it has completed four engineering runs of AP-SA02 at its manufacturing facility in Los Angeles, with production of clinical trial material identified as the next planned step.</p> <p>The company said its Phase 3 study remains on track to begin http://www.streetinsider.com/FDA/Armata+submits+Phase+3+protocol+to+FDA+for+bacteriophage+drug+AP-SA02/26786839.html Mon, 20 Jul 2026 07:00:32 -0400 A.06822034 A.38032151 A.40958841 ARMP O.00168871 O.00366519 O.20026344 O.36670513 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Achieves+Key+Progress+Across+Clinical%2C+Regulatory+and+Manufacturing+Activities+Supporting+Planned+Phase+3+Initiation+of+AP-SA02/26786824.html <div class="xn-content"> <p class="prntac"><i>FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meeting</i></p><p class="prntac"><i>Four AP-SA02 engineering runs completed; clinical trial material production is the next planned manufacturing step</i></p><p class="prntac"><i>Phase 3 superiority study remains on track to initiate in the second half of 2026</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced significant clinical, regulatory, manufacturing http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Achieves+Key+Progress+Across+Clinical%2C+Regulatory+and+Manufacturing+Activities+Supporting+Planned+Phase+3+Initiation+of+AP-SA02/26786824.html Mon, 20 Jul 2026 07:00:00 -0400 A.06822034 A.38032151 A.40958841 ARMP O.00168871 O.00366519 O.20026344 O.36670513 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Achieves+Key+Progress+Across+Clinical%2C+Regulatory+and+Manufacturing+Activities+Supporting+Planned+Phase+3+Initiation+of+AP-SA02/26786824.html <div class="xn-content"> <p class="prntac"><i>FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meeting</i></p><p class="prntac"><i>Four AP-SA02 engineering runs completed; clinical trial material production is the next planned manufacturing step</i></p><p class="prntac"><i>Phase 3 superiority study remains on track to initiate in the second half of 2026</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced significant clinical, regulatory, manufacturing http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Achieves+Key+Progress+Across+Clinical%2C+Regulatory+and+Manufacturing+Activities+Supporting+Planned+Phase+3+Initiation+of+AP-SA02/26786824.html Mon, 20 Jul 2026 07:00:00 -0400 A.06822034 A.38032151 A.40958841 ARMP O.00168871 O.00366519 O.20026344 O.36670513 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Achieves+Key+Progress+Across+Clinical%2C+Regulatory+and+Manufacturing+Activities+Supporting+Planned+Phase+3+Initiation+of+AP-SA02/26786824.html <div class="xn-content"> <p class="prntac"><i>FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meeting</i></p><p class="prntac"><i>Four AP-SA02 engineering runs completed; clinical trial material production is the next planned manufacturing step</i></p><p class="prntac"><i>Phase 3 superiority study remains on track to initiate in the second half of 2026</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced significant clinical, regulatory, manufacturing http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Achieves+Key+Progress+Across+Clinical%2C+Regulatory+and+Manufacturing+Activities+Supporting+Planned+Phase+3+Initiation+of+AP-SA02/26786824.html Mon, 20 Jul 2026 07:00:00 -0400 A.06822034 A.38032151 A.40958841 ARMP O.00168871 O.00366519 O.20026344 O.36670513 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Achieves+Key+Progress+Across+Clinical%2C+Regulatory+and+Manufacturing+Activities+Supporting+Planned+Phase+3+Initiation+of+AP-SA02/26786824.html <div class="xn-content"> <p class="prntac"><i>FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meeting</i></p><p class="prntac"><i>Four AP-SA02 engineering runs completed; clinical trial material production is the next planned manufacturing step</i></p><p class="prntac"><i>Phase 3 superiority study remains on track to initiate in the second half of 2026</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced significant clinical, regulatory, manufacturing http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Achieves+Key+Progress+Across+Clinical%2C+Regulatory+and+Manufacturing+Activities+Supporting+Planned+Phase+3+Initiation+of+AP-SA02/26786824.html Mon, 20 Jul 2026 07:00:00 -0400 A.06822034 A.38032151 A.40958841 ARMP O.00168871 O.00366519 O.20026344 O.36670513 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Achieves+Key+Progress+Across+Clinical%2C+Regulatory+and+Manufacturing+Activities+Supporting+Planned+Phase+3+Initiation+of+AP-SA02/26786824.html <div class="xn-content"> <p class="prntac"><i>FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meeting</i></p><p class="prntac"><i>Four AP-SA02 engineering runs completed; clinical trial material production is the next planned manufacturing step</i></p><p class="prntac"><i>Phase 3 superiority study remains on track to initiate in the second half of 2026</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced significant clinical, regulatory, manufacturing http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Achieves+Key+Progress+Across+Clinical%2C+Regulatory+and+Manufacturing+Activities+Supporting+Planned+Phase+3+Initiation+of+AP-SA02/26786824.html Mon, 20 Jul 2026 07:00:00 -0400 A.06822034 A.38032151 A.40958841 ARMP O.00168871 O.00366519 O.20026344 O.36670513 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Achieves+Key+Progress+Across+Clinical%2C+Regulatory+and+Manufacturing+Activities+Supporting+Planned+Phase+3+Initiation+of+AP-SA02/26786824.html <div class="xn-content"> <p class="prntac"><i>FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meeting</i></p><p class="prntac"><i>Four AP-SA02 engineering runs completed; clinical trial material production is the next planned manufacturing step</i></p><p class="prntac"><i>Phase 3 superiority study remains on track to initiate in the second half of 2026</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced significant clinical, regulatory, manufacturing http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Achieves+Key+Progress+Across+Clinical%2C+Regulatory+and+Manufacturing+Activities+Supporting+Planned+Phase+3+Initiation+of+AP-SA02/26786824.html Mon, 20 Jul 2026 07:00:00 -0400 A.06822034 A.38032151 A.40958841 ARMP O.00168871 O.00366519 O.20026344 O.36670513 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Achieves+Key+Progress+Across+Clinical%2C+Regulatory+and+Manufacturing+Activities+Supporting+Planned+Phase+3+Initiation+of+AP-SA02/26786824.html <div class="xn-content"> <p class="prntac"><i>FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meeting</i></p><p class="prntac"><i>Four AP-SA02 engineering runs completed; clinical trial material production is the next planned manufacturing step</i></p><p class="prntac"><i>Phase 3 superiority study remains on track to initiate in the second half of 2026</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced significant clinical, regulatory, manufacturing http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Achieves+Key+Progress+Across+Clinical%2C+Regulatory+and+Manufacturing+Activities+Supporting+Planned+Phase+3+Initiation+of+AP-SA02/26786824.html Mon, 20 Jul 2026 07:00:00 -0400 A.06822034 A.38032151 A.40958841 ARMP O.00168871 O.00366519 O.20026344 O.36670513 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Achieves+Key+Progress+Across+Clinical%2C+Regulatory+and+Manufacturing+Activities+Supporting+Planned+Phase+3+Initiation+of+AP-SA02/26786824.html <div class="xn-content"> <p class="prntac"><i>FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meeting</i></p><p class="prntac"><i>Four AP-SA02 engineering runs completed; clinical trial material production is the next planned manufacturing step</i></p><p class="prntac"><i>Phase 3 superiority study remains on track to initiate in the second half of 2026</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced significant clinical, regulatory, manufacturing http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Achieves+Key+Progress+Across+Clinical%2C+Regulatory+and+Manufacturing+Activities+Supporting+Planned+Phase+3+Initiation+of+AP-SA02/26786824.html Mon, 20 Jul 2026 07:00:00 -0400 A.06822034 A.38032151 A.40958841 ARMP O.00168871 O.00366519 O.20026344 O.36670513 http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Achieves+Key+Progress+Across+Clinical%2C+Regulatory+and+Manufacturing+Activities+Supporting+Planned+Phase+3+Initiation+of+AP-SA02/26786824.html <div class="xn-content"> <p class="prntac"><i>FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meeting</i></p><p class="prntac"><i>Four AP-SA02 engineering runs completed; clinical trial material production is the next planned manufacturing step</i></p><p class="prntac"><i>Phase 3 superiority study remains on track to initiate in the second half of 2026</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced significant clinical, regulatory, manufacturing http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Achieves+Key+Progress+Across+Clinical%2C+Regulatory+and+Manufacturing+Activities+Supporting+Planned+Phase+3+Initiation+of+AP-SA02/26786824.html Mon, 20 Jul 2026 07:00:00 -0400 A.06822034 A.38032151 A.40958841 ARMP O.00168871 O.00366519 O.20026344 O.36670513 http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Achieves+Key+Progress+Across+Clinical%2C+Regulatory+and+Manufacturing+Activities+Supporting+Planned+Phase+3+Initiation+of+AP-SA02/26786824.html <div class="xn-content"> <p class="prntac"><i>FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meeting</i></p><p class="prntac"><i>Four AP-SA02 engineering runs completed; clinical trial material production is the next planned manufacturing step</i></p><p class="prntac"><i>Phase 3 superiority study remains on track to initiate in the second half of 2026</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced significant clinical, regulatory, manufacturing http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Achieves+Key+Progress+Across+Clinical%2C+Regulatory+and+Manufacturing+Activities+Supporting+Planned+Phase+3+Initiation+of+AP-SA02/26786824.html Mon, 20 Jul 2026 07:00:00 -0400 A.06822034 A.38032151 A.40958841 ARMP O.00168871 O.00366519 O.20026344 O.36670513 http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Achieves+Key+Progress+Across+Clinical%2C+Regulatory+and+Manufacturing+Activities+Supporting+Planned+Phase+3+Initiation+of+AP-SA02/26786824.html <div class="xn-content"> <p class="prntac"><i>FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meeting</i></p><p class="prntac"><i>Four AP-SA02 engineering runs completed; clinical trial material production is the next planned manufacturing step</i></p><p class="prntac"><i>Phase 3 superiority study remains on track to initiate in the second half of 2026</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced significant clinical, regulatory, manufacturing http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Achieves+Key+Progress+Across+Clinical%2C+Regulatory+and+Manufacturing+Activities+Supporting+Planned+Phase+3+Initiation+of+AP-SA02/26786824.html Mon, 20 Jul 2026 07:00:00 -0400 A.06822034 A.38032151 A.40958841 ARMP O.00168871 O.00366519 O.20026344 O.36670513 http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Achieves+Key+Progress+Across+Clinical%2C+Regulatory+and+Manufacturing+Activities+Supporting+Planned+Phase+3+Initiation+of+AP-SA02/26786824.html <div class="xn-content"> <p class="prntac"><i>FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meeting</i></p><p class="prntac"><i>Four AP-SA02 engineering runs completed; clinical trial material production is the next planned manufacturing step</i></p><p class="prntac"><i>Phase 3 superiority study remains on track to initiate in the second half of 2026</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced significant clinical, regulatory, manufacturing http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Achieves+Key+Progress+Across+Clinical%2C+Regulatory+and+Manufacturing+Activities+Supporting+Planned+Phase+3+Initiation+of+AP-SA02/26786824.html Mon, 20 Jul 2026 07:00:00 -0400 A.06822034 A.38032151 A.40958841 ARMP O.00168871 O.00366519 O.20026344 O.36670513 http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Achieves+Key+Progress+Across+Clinical%2C+Regulatory+and+Manufacturing+Activities+Supporting+Planned+Phase+3+Initiation+of+AP-SA02/26786824.html <div class="xn-content"> <p class="prntac"><i>FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meeting</i></p><p class="prntac"><i>Four AP-SA02 engineering runs completed; clinical trial material production is the next planned manufacturing step</i></p><p class="prntac"><i>Phase 3 superiority study remains on track to initiate in the second half of 2026</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>July 20, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced significant clinical, regulatory, manufacturing http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Achieves+Key+Progress+Across+Clinical%2C+Regulatory+and+Manufacturing+Activities+Supporting+Planned+Phase+3+Initiation+of+AP-SA02/26786824.html Mon, 20 Jul 2026 07:00:00 -0400 A.06822034 A.38032151 A.40958841 ARMP O.00168871 O.00366519 O.20026344 O.36670513